MDT trades against a final fair-value range of $78.26-$113.75, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $78.3, high $114, with mid-point at $95.9.
Questo report non è ancora stato tradotto. Aggiorna tra qualche minuto una volta che la coda di traduzione avrà recuperato.
§1 Sintesi
Composite fair value $96 with high case $114.
Implied upside of 24.8% to fair value.
Moat 9/10 · confidence 88/100 · Mature dividend.
Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$96
Margin of safety
+19.9%
Confidence
88/100
Moat
9/10
Educational analysis only — not financial advice. Always do your own due diligence.
$76.82Price
Low $78.26
Mid $95.89
High $113.75
MDT trades against a final fair-value range of $78.26-$113.75, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.
Immense scale in the global
Immense scale in the global medical devices industry.
High switching costs for healthcare
High switching costs for healthcare providers.
Cycle upside
Adoption of next-generation therapies in Diabetes and Cardiovascular drives operating leverage and multiple expansion.
§2 Scenario ribassista
A prolonged period of sluggish top-line growth combined with intense pricing pressure and hospital capital constraints severely compresses operating margins below the 19.5% baseline, threatening Medtronic's reliable free cash flow and forcing a cut to its high dividend payout.
Come questa tesi può fallire
Pipeline Stagnation
· Medium
Regulatory and clinical trial setbacks for Cardiovascular and Diabetes pipelines stall product cycles, allowing competitors to permanently seize market share.
FV impact
-20%
Trigger
12-24 months
Hospital Capital Freeze
· Low
Macroeconomic pressures force severe hospital capital constraints and widespread deferral of elective procedures, crushing revenue growth to negative territory.
FV impact
-25%
Trigger
6-12 months
Dividend Yield Trap
· Low
Pricing pressure and margin erosion reduce free cash flow such that the 79% dividend payout becomes unsustainable, triggering massive multiple compression.
FV impact
-30%
Trigger
24-36 months
Segnali di allerta precoce da monitorare
Metrica
Attuale
Soglia di attivazione
Internal valuation cross-checks forward estimates drop below the 1.5% minimum growth hurdle.
Monitor
Deterioration versus the report thesis
Capex to D&A ratio rises above 1.0 without corresponding revenue lift.
Monitor
Deterioration versus the report thesis
Operating margins fall structurally below the established 19.5% baseline.
Monitor
Deterioration versus the report thesis
Dividend payout ratio exceeds 90% of sustainable free cash flow.
Monitor
Deterioration versus the report thesis
Major clinical trial failures or FDA rejections in key growth segments.
Based on our latest analysis, MDT looks meaningfully undervalued. The current price is $76.8 versus a composite fair-value midpoint of $95.9 (range $78.3–$114), which implies roughly 24.8% upside to the midpoint.
Our composite fair-value range for MDT is $78.3–$114, with a midpoint of $95.9. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for MDT's archetype.
Our current rating for MDT is Buy with a confidence score of 88/100. MDT is rated Buy at $76.82 versus the reconciled fair value midpoint of $95.89, implying +24.82% upside/downside. Confidence is separately disclosed at 88/100. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for MDT are: Pipeline Stagnation; Hospital Capital Freeze; Dividend Yield Trap. The single biggest risk is Pipeline Stagnation: Regulatory and clinical trial setbacks for Cardiovascular and Diabetes pipelines stall product cycles, allowing competitors to permanently seize market share.
Our current rating for MDT is Buy, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($78.3–$114) versus the current price of $76.8.
MDT is classified as a mature-dividend stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for MDT.
